LHLucas Villas Bôas Hoelz

Lucas Villas Bôas Hoelz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lucas Villas Bôas Hoelz has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Conformational dynamics and energetic landscape of the SARS-CoV-2 nsp12 with and without accessory proteins: new insights on this potential therapeutic target against COVID-19

    by Tácio Vinício Amorim Fernandes, Frederico Silva Castelo-Branco, Vinícius Santos De Pontes, Bruna Costa Zorzanelli, Mônica Macedo Bastos, Nubia Boechat, Lucas Villas Bôas Hoelz

  • Open Access

    Cruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates

    by Caroline Rodrigues Chaves dos Reis, Hellen Valério Chaves Moura de Souza, Lidia Corrêa Parra, Guilber Valério Chaves Moura de Souza, Bruna Costa Zorzanelli, Nubia Boechat, Lucas Villas Bôas Hoelz, Tácio Vinício Amorim Fernandes

    Over three decades, cruzain, the principal cysteine protease of Trypanosoma cruzi and a validated drug target for Chagas disease, has accumulated 215 inhibitors with IC 50 ≤ 1 μM, more than 30 crystal structures, and no clinical candidates. This review argues that the resulting translational paradox reflects not target invalidity, but a persistent strategic mismatch between how cruzain inhibitors have been optimised and what intracellular efficacy requires. Across peptidyl vinyl sulfones, non‐peptidic scaffolds, and thiosemicarbazones, enzymatic potency has been systematically prioritised over the coupled determinants of intracellular exposure: permeability, metabolic stability, and cathepsin selectivity. Each inhibitor class fails for a distinct proximal reason, and these failures converge on the same optimisation bias. Computational approaches (docking, molecular dynamics, free‐energy perturbation and machine‐learning QSAR) have been applied with increasing sophistication, but against affinity‐centred objectives that underrepresent exposure constraints. As its principal contribution, this work proposes a multiparametric optimisation framework, provisional viability benchmarks, and a feasibility‐envelope concept that reframes cruzain inhibitor discovery as a constraint‐satisfaction rather than a potency‐maximisation problem. The framework outlines provisional quantitative criteria that a next‐generation cruzain lead would likely need to satisfy and explains why structurally tractable intracellular cysteine protease targets can remain clinically unrealised.

  • Study of the dynamic behavior of the cruzain enzyme in free and complexed forms with competitive and noncovalent benzimidazole inhibitors

    by Caroline Rodrigues Chaves dos Reis, Hellen Valério Chaves Moura de Souza, Rennan Papaleo Paes Leme, Frederico Silva Castelo-Branco, Tácio Vinício Amorim Fernandes, Núbia Boechat, Luiza Rosaria Sousa Dias, Lucas Villas Bôas Hoelz

    There are only two drugs for the treatment of Chagas disease, namely, nifurtimox and benznidazole, that can cause several adverse effects. Despite the effectiveness of these drugs in the disease's acute phase, they are not recognized as curative in the chronic phase, establishing the need for more effective treatment in all stages of the disease. Cruzain is an enzyme that plays a vital role in the life cycle of the etiologic agent, the protozoan Trypanosoma cruzi, being relevant as a therapeutic target in the planning of new drugs. Using molecular docking and dynamics simulations, we have investigated the structural and dynamic factors that can be involved in the enzyme inhibition process at the atomic-molecular level by benzimidazole compounds that are potent cruzain inhibitors with in vitro trypanocidal activity. The study suggests that these inhibitors bind cruzain through steric and hydrogen bonding interactions without altering its secondary structure content and protein compaction. Besides, we observed that these inhibitors decrease the correlation of movements between Cα-atoms of cruzain, increasing the number of atomic communities, mainly in the α-helix that presents the catalytic Cys25 residue. As expected, we also observed a correlation between the inhibitory activity of each inhibitor and their respective binding-free energies, reinforcing that the affinity of the complexes seems to be a relevant factor for enzymatic inhibition. Hence, the results presented in this work contribute to a better understanding of the cruzain enzyme inhibition mechanism through competitive and non-covalent inhibitors. Communicated by Ramaswamy H. Sarma


  • The Medicinal Chemistry of 3-nitro-1,2,4-triazoles: Focus on Infectious Diseases

    by Rodolfo Rodrigo Florido França, Cheyene Almeida Celestino Menozzi, Frederico Silva Castelo-Branco, Lucas Villas Bôas Hoelz, Nubia Boechat

    : Infectious diseases are among the leading causes of death worldwide, especially in developing countries. The historical lack of interest of the pharmaceutical industry in developing new drugs against many of these diseases, such as tuberculosis, leishmaniasis, Chagas disease, sleeping sickness, and fungal infections, has left millions of individuals dependent on old treatments that are often ineffective and present different adverse effects. In this sense, new substances against these diseases must be identified. A class of substances that has stood out in the search for new drugs against these diseases is azole derivatives. Within this class, the 3-nitro-1,2,4-triazole nucleus has attracted increasing interest due to its potential, specifically when compared to the 1,2,4-triazole nucleus without the presence of the nitro group, and also in relation to the 2-nitroimidazole nucleus, showing greater potency and selectivity against different etiological agents. This is even more relevant considering that 3-nitro-1,2,4-triazolic substances can promote their activity through different mechanisms of action, such as the inhibition of ergosterol biosynthesis and also via activation by the nitroreductase enzyme, which can avoid the development of cross-resistance. Therefore, in this review, the medicinal chemistry of nitrotriazoles is discussed through the analysis of their potential in terms of biological activity against the etiological agents of several diseases, such as Chagas disease, sleeping sickness and leishmaniasis, caused by kinetoplastid parasites, tuberculosis, caused by the mycobacteria Mycobacterium tuberculosis, and against different species of pathogenic fungi. In addition, aspects related to enzymatic activities, molecular modeling and organic synthesis of these substances are also addressed.


  • Open Access

    Synthesis of benzoylthiourea derivatives and analysis of their antibacterial performance against planktonic Staphylococcus aureus and its biofilms

    by Luiz C.S. Pinheiro, Lucas V.B. Hoelz, Maria de Lourdes G. Ferreira, Larissa G. Oliveira, Renata Freire Alves Pereira, Amanda Mendes Do Valle, Lialyz Soares Pereira André, Julia Scaffo, Felipe Ramos Pinheiro, Tainara Aparecida Nunes Ribeiro, et al.

    Following the appearance of several antimicrobial agents to control the spread of infections, two major challenges have emerged: 1‐ the occurrence and blowout of multiresistant bacteria and the increase of chronic diseases, and 2‐ difficult‐to‐eradicate infections. In this study, we tested five benzoylthiourea derivatives for their ability to inhibit and stop bacterial growth and evaluated the possible influence of 1,2,4‐triazolyl‐benzoylthiourea derivative 4 on the formation and eradication of S. aureus biofilms. Benzoylthiourea derivatives 4 , 6 , 10 , 11, and 13 were obtained in one or two steps with low cost and subjected to tests to identify their minimum inhibitory concentration and minimum bactericidal concentration. In vitro tests were also performed to assess their effects on biofilm formation and in preformed biofilms and scanning electron microscopy was used to visualize the effects on biofilm formation. The 1,2,4‐triazolyl‐benzoylthiourea derivative 4 showed bacteriostatic activity against the Staphylococcus aureus HU25 clinical strain with an minimum inhibitory concentration (MIC) of 16 µg.mL‐1, which is below the toxic concentration (at 2,500 µg.mL‐1, 62.25% of the cells remained viable). Compound 4 also effectively prevented biofilm formation at the three subinhibitory concentrations tested (1/2 MIC, 1/4 MIC and 1/8 MIC) as confirmed by SEM. For breakdown of formed biofilms, the main influence was at a subinhibitory concentration (1/2 MIC). These findings make compound 4 a strong candidate for studies on the development of new antimicrobial and antibiofilm agents.


  • Cytopathology smears from autopsies: A viable storage method for molecular analysis

    by Lucas Hoelz, Arya Mesgary, Eduardo Achar, Marcela Gimenez, Mauro Saieg

    Introduction: Cytology appears to be a viable option to histological samples for proper storage and maintenance of autopsy material for DNA extraction and analysis. In the present study, we tested the feasibility of using archived air‐dried smears produced at the time of the autopsy for simple molecular analysis, comparing quantity and quality of the DNA extracted from the smears to that of correspondent histological specimens.Methods: Air‐dried cytological smears were obtained from scrapings of exactly the same areas collected for histological study. DNA was extracted using a commercially available protocol from all samples, with calculation of purity ratio and overall concentration. The integrity of the extracted DNA was also verified through conventional polymerase chain reaction (PCR).Results: Five cases of lung tumours (2 small cell carcinomas and 3 adenocarcinomas) were collected. Percentage of tumour cells and necrosis ranged from 30% to 90% and from 10% to 40%, respectively, in the cytological preparations, and from 50% to 90% and from 10% to 80%, respectively, in the histological preparations. Purity ratio (260/280) had a median of 1.87 in cytology vs 1.94 in histology. Mean DNA concentration among the cytological preparations was 2653 ng/mL (range 1684‐3980 ng/mL) vs 757.2 ng/mL among the histological preparations (range 456‐1829 ng/mL. DNA from all five cases of cytology was successfully amplified by conventional PCR, in contrast to none from the histology specimens.Conclusions: Archived air‐dried smears scraped from tumoural lesions in autopsies have proven to yield a good concentration of quality DNA for conventional PCR, with better results than formalin‐fixed paraffin embedded material.


  • Phenylamino-pyrimidine (PAP) Privileged Structure: Synthesis and Medicinal Applications

    by Luiz Claudio Ferreira Pimentel, Anna Claudia Cunha, Lucas Villas Boas Hoelz, Henayle Fernandes Canzian, Debora Inacio Leite Firmino Marinho, Nubia Boechat, Monica Macedo Bastos

    The phenylamino-pyrimidine (PAP) nucleus has been demonstrated to be useful for the development of new drugs and is present in a wide variety of antiretroviral agents and tyrosine kinase inhibitors (TKIs). This review aims to evaluate the application of PAP derivatives in drugs and other bioactive compounds. It was concluded that PAP derivatives are still worth exploring, as they may provide highly competitive ATP TKI’s with nano/picomolar activity.


  • Open Access

    Correction: Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication

    by Carolina Q. Sacramento, Gabrielle R. de Melo, Caroline S. de Freitas, Natasha Rocha, Lucas Villas Bôas Hoelz, Milene Miranda, Natalia Fintelman-Rodrigues, Andressa Marttorelli, André C. Ferreira, Giselle Barbosa-Lima, et al.

    Scientific Reports 7: Article number: 40920; published online 18 January 2017; updated on 24 April 2017 The Competing Financial Interests section in this Article is incorrect and should read: “Dr. Karin Brüning is a member of the BMK consortium, able to produce sofosbuvir”.


  • Tribromoisocyanuric Acid (TBCA)

    by Lucas V. B. Hoelz

    This paper provides a description of tribromoisocyanuric acid (TBCA), a new reagent used as a source of electrophilic bromine (Br+) in organic synthesis, including in Green Chemistry procedures. Its applications embrace the bromination of alkenes, ß-dicarbonyl compounds and deactivated arenes, as well as oxidations of urazoles, bisurazoles, and thiols.